Panoxyvir ltd. is a life science pharma company developing a new concept of wide-spectrum antiviral drugs, with a focus on relevant respiratory viral pathogens, including rhinoviruses and emerging coronaviruses. Panoxyvir technological platform is based on evolutionary-shaped physiological molecules endowed with high biocompatibility, peculiar mechanism of action, and a high genetic barrier that does not select resistant viral strains. These unique characteristics give the Panoxyvir business project a strong competitive advantage over traditional antiviral development programs. The implementation of the Panoxyvir team with high-profile expert consultants has made it possible to reach important milestones in preclinical development and to outline a clear path leading to the entry-into-human phase.